Pfizer is entering in vivo CAR-T through a deal with China’s Starna Therapeutics that could reach $2.6 billion, adding three preclinical autoimmune programs to its pipeline and widening its use of RNA-based approaches. The companies said Pfizer will pay $330 million upfront for ex-China rights, with the remainder tied to up to $2.3 billion in milestone payments plus royalties.
The transaction marks Pfizer’s first move into in vivo CAR-T specifically, even though the company has previously worked on ex vivo CAR-T in oncology and already has in vivo experience in gene editing through its collaboration with Beam Therapeutics. Strategically, the deal places Pfizer in two areas that have drawn sustained attention from large drugmakers: in vivo therapies designed to generate CAR-T cells inside the body, and the use of CAR-T approaches in autoimmune disease rather than cancer alone.
The Programs
Pfizer said the three Starna candidates are focused on treating autoimmune diseases and are currently in “pre-IND” development. Under the agreement, Pfizer will lead clinical development outside Greater China, while retaining the option to add China rights later.
The current plan is to manufacture finished drug product for early trials at Pfizer’s U.S. sites. That detail matters because it shows the company is not just licensing molecules; it is also preparing to apply its own development and manufacturing network to programs that are still at a very early stage.
Starna is developing RNA medicines delivered through a targeted lipid nanoparticle platform. Pfizer said its own experience in developing and manufacturing RNA-based medicines globally was part of the rationale for the deal. BioSpace also reported that Pfizer secured rights to use Starna’s in vivo CAR-T technology for inflammation and immunology and oncology indications, and that a separate research collaboration could yield future compounds, though details were not disclosed.
The Strategic Picture
The immediate pipeline effect is in immunology. Pfizer’s Michael Vincent, chief inflammation and immunology officer, said in vivo CAR-T is a promising approach for autoimmune diseases, particularly for patients whose current options fall short. A Pfizer spokesperson told BioSpace that B-cell depletion therapies have been an area of interest for the company, framing the Starna alliance as an extension of that work.
The broader industry signal is that Pfizer is following a deal pattern already established by peers. Eli Lilly has acquired two in vivo CAR-T biotechs this year, Kelonia Therapeutics and Orna Therapeutics, with the Orna deal focused on autoimmune conditions. At the same time, Kyverna Therapeutics is awaiting an FDA decision on what could become the first approval for an autoimmune CAR-T therapy. Pfizer is therefore not opening a new market category on its own; it is joining a race that has already begun to define where next-generation cell therapy may move beyond oncology.
The structure also fits Pfizer’s current external innovation strategy in China. BioSpace noted that the company signed a 10-asset deal with Innovent in May that could ultimately pay out $10.5 billion, and in February agreed to pay Sciwind Biosciences $495 million upfront to market an obesity treatment in the country. The Starna agreement adds another China-originated bet, but in a modality that is earlier and riskier than late-stage in-licensing.
The Road Here
The Starna pact landed the same day that BioSpace highlighted CEO Albert Bourla’s comments about China’s rise as a competitive force in biopharma. Speaking at the Jefferies Global Healthcare Conference in London, Bourla said that by year 2030 Chinese companies would represent Pfizer’s major competition, arguing that they are moving at half the cost and three to four times the speed.
Bourla tied Pfizer’s response to AI, describing it as the company’s biggest lever to build a future organization that can operate at three to four times the speed and half the cost. That does not make the Starna deal an AI announcement, but it does give it a sharper context: Pfizer is pairing its public call for higher development efficiency with external deals sourced from a market it sees as becoming structurally more competitive.
For Pfizer, the signal is less about one preclinical transaction than about portfolio architecture. The company is using business development to access technologies that could shorten or simplify how complex therapies are delivered, while also leaning into disease areas such as autoimmune conditions where commercial demand is broad and current treatment gaps remain significant.




